THE UK CHARITY FOR TRIPLE NEGATIVE BREAST CANCER
UK Charity for TNBC is a charity dedicated to helping people with TNBC in the UK by providing them with better information and support, and by funding research into TNBC.
Objects
THE OBJECTS OF THE CIO ARE, FOR THE PUBLIC BENEFIT:1. TO ADVANCE THE EDUCATION OF THE GENERAL PUBLIC BY THE SUPPORT AND PROMOTION OF RESEARCH INTO THE CAUSES AND TREATMENTS OF TRIPLE NEGATIVE BREAST CANCER ON TERMS THAT THE USEFUL RESULTS OF SUCH RESEARCH ARE PUBLISHED;2. TO PROMOTE AND PROTECT THE PHYSICAL AND MENTAL HEALTH OF SUFFERERS OF TRIPLE NEGATIVE BREAST CANCER BY:2.1. RAISING AWARENESS OF THE CAUSES, IMPACT AND PREVENTION OF TRIPLE NEGATIVE BREAST CANCER; AND2.2. THROUGH THE PROVISION OF SUCH SUPPORT DIRECTED TO RELIEVING THE NEEDS OF SUFFERERS AS THE TRUSTEES MAY DETERMINE.
Financial health, per its FY2025 accounts
The accounts state that the charity ended the year with a healthy cash position of £70,504, funded largely by pharmaceutical companies. The independent examiner confirmed that no material matters came to their attention during the examination of the accounts for the year ended 31 December 2024.
What the accounts disclose
“This enabled us to make the required annual submission to the England and Wales Charity Commissioners, albeit a little bit late!”
Trustees
- Dr CLAIRE ELIZABETH BERTRAND
- LOUISE JANE HARRISON
- PROFESSOR CHRISTOPHER JOHN TWELVES
- ROBIN ARTHUR JOHN WOOLCOCK
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 01/01/2025 | £72k | £84k |
| 01/01/2024 | £79k | £27k |
| 01/01/2023 | £23k | £9k |
| 01/01/2022 | £13k | £323 |
Common questions
Is THE UK CHARITY FOR TRIPLE NEGATIVE BREAST CANCER financially healthy?
Per its FY2025 accounts: The accounts state that the charity ended the year with a healthy cash position of £70,504, funded largely by pharmaceutical companies. The independent examiner confirmed that no material matters came to their attention during the examination of the accounts for the year ended 31 December 2024. Its FY2025 accounts were independently examined.